Equities analysts expect Thermo Fisher Scientific Inc. (NYSE:TMO) to report sales of $5.91 billion for the current quarter, according to Zacks Investment Research. Seven analysts have provided estimates for Thermo Fisher Scientific’s earnings, with estimates ranging from $5.87 billion to $6.02 billion. Thermo Fisher Scientific reported sales of $4.99 billion during the same quarter last year, which would suggest a positive year over year growth rate of 18.4%. The firm is expected to report its next quarterly earnings results before the market opens on Wednesday, July 25th.

On average, analysts expect that Thermo Fisher Scientific will report full-year sales of $23.78 billion for the current fiscal year, with estimates ranging from $23.76 billion to $23.81 billion. For the next year, analysts anticipate that the business will post sales of $24.95 billion per share, with estimates ranging from $24.82 billion to $25.16 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover Thermo Fisher Scientific.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, April 25th. The medical research company reported $2.50 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.42 by $0.08. The company had revenue of $5.85 billion for the quarter, compared to the consensus estimate of $5.62 billion. Thermo Fisher Scientific had a net margin of 10.24% and a return on equity of 16.09%. The firm’s revenue for the quarter was up 22.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.08 earnings per share.

TMO has been the topic of a number of research analyst reports. Zacks Investment Research downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Thursday, April 5th. Morgan Stanley increased their price objective on shares of Thermo Fisher Scientific from $216.00 to $230.00 and gave the company an “overweight” rating in a research report on Thursday, April 26th. Finally, ValuEngine downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Wednesday, June 20th. Two research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Thermo Fisher Scientific currently has an average rating of “Buy” and a consensus target price of $226.33.

Thermo Fisher Scientific stock traded down $4.51 during midday trading on Friday, reaching $209.65. 67,074 shares of the company traded hands, compared to its average volume of 1,223,495. The company has a market cap of $85.22 billion, a price-to-earnings ratio of 22.10, a price-to-earnings-growth ratio of 1.55 and a beta of 1.10. Thermo Fisher Scientific has a 12 month low of $170.07 and a 12 month high of $226.44. The company has a quick ratio of 0.95, a current ratio of 1.36 and a debt-to-equity ratio of 0.69.

The firm also recently announced a quarterly dividend, which will be paid on Monday, July 16th. Shareholders of record on Friday, June 15th will be issued a dividend of $0.17 per share. The ex-dividend date is Thursday, June 14th. This represents a $0.68 dividend on an annualized basis and a yield of 0.32%. Thermo Fisher Scientific’s dividend payout ratio is currently 7.17%.

In other Thermo Fisher Scientific news, Director C Martin Harris sold 206 shares of the company’s stock in a transaction that occurred on Friday, May 18th. The shares were sold at an average price of $214.43, for a total transaction of $44,172.58. Following the completion of the sale, the director now directly owns 5,106 shares of the company’s stock, valued at $1,094,879.58. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Marc N. Casper sold 50,000 shares of the stock in a transaction on Wednesday, June 13th. The stock was sold at an average price of $217.71, for a total transaction of $10,885,500.00. Following the completion of the sale, the chief executive officer now directly owns 272,122 shares of the company’s stock, valued at $59,243,680.62. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 97,706 shares of company stock valued at $21,125,673. 0.49% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Front Row Advisors LLC increased its stake in shares of Thermo Fisher Scientific by 4.0% in the first quarter. Front Row Advisors LLC now owns 6,049 shares of the medical research company’s stock worth $1,249,000 after purchasing an additional 234 shares in the last quarter. Carnick & Kubik Group LLC increased its stake in shares of Thermo Fisher Scientific by 3.3% in the first quarter. Carnick & Kubik Group LLC now owns 8,208 shares of the medical research company’s stock worth $1,695,000 after purchasing an additional 260 shares in the last quarter. Private Advisor Group LLC increased its stake in shares of Thermo Fisher Scientific by 3.2% in the first quarter. Private Advisor Group LLC now owns 8,481 shares of the medical research company’s stock worth $1,753,000 after purchasing an additional 260 shares in the last quarter. Tdam USA Inc. increased its stake in shares of Thermo Fisher Scientific by 4.4% in the first quarter. Tdam USA Inc. now owns 6,259 shares of the medical research company’s stock worth $1,292,000 after purchasing an additional 264 shares in the last quarter. Finally, Lido Advisors LLC increased its stake in shares of Thermo Fisher Scientific by 6.4% in the fourth quarter. Lido Advisors LLC now owns 4,453 shares of the medical research company’s stock worth $845,000 after purchasing an additional 267 shares in the last quarter. 85.76% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Get a free copy of the Zacks research report on Thermo Fisher Scientific (TMO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.